Johnson & Johnson (JNJ) Stock: Price, Trend, Options & Financials
Johnson & Johnson's price regime, relative strength, unusual-options history, curated-manager ownership and filed fundamentals — joined into one dated stock intelligence page.
What the evidence says now
JNJ closed at $270.24 on Aug 21, 2026. The price is +6.0% from its 50-day average and +16.6% from its 200-day average, which places it in the rules-based “established uptrend” regime. The relative-strength check: over three months the stock returned +16.6%, beating SPY by 13.5%. It remains 2.3% below its 52-week high.
Sources, methodology & freshnessLast updated 2026-08-21 · Open ↓Close ↑
The close is +6.0% from its 50-day average and +16.6% from its 200-day average. Over three months, JNJ returned +16.6% versus +3.1% for SPY.
- vs 50-day
- +6.0%
- vs 200-day
- +16.6%
- From 52W high
- -2.3%
Descriptive, not predictive. “Uptrend” is a rules-based reading of the close and moving averages; it is not a rating, price target or recommendation.
Price & regime
One year of daily price and volume
252 split-adjusted sessions · candles above, share volume below
Unusual options — attention, not intent
JNJ appeared in a UOA top-30 list on 2 of 62 archived scanner sessions: 2 call-side, 0 put-side and 0 on both lists. The latest session did not place it in either top 30. Its larger composite score was -0.17, below the 1.5 “strong” threshold. That is repeated options attention, not proof of bullish trade initiation.
| Recent flag | Call rank | Put rank |
|---|---|---|
| 2026-07-10 | #23 | — |
| 2026-06-18 | #17 | — |
Latest chain snapshot
2026-08-21Strong-signature cutoff: 1.5. Current OTM volume/OI: 0.111 calls, 0.082 puts.
Curated-manager ownership
1 of the 20 managers in the project's curated 13F set reported a long Johnson & Johnson position in their latest filing, worth $6M in aggregate at each filing's reported value. This is a focused manager panel, not the complete institutional holder list.
| Fund / manager | Position value | Portfolio | Shares | Quarter change | Report date |
|---|---|---|---|---|---|
Baron Capital Group Ron Baron · JNJ | $6M | 0.01% | 25,172 | +11.9% increased | 2026-06-30 |
Filed fundamentals — latest snapshot
Go deeper into the filings
The dedicated Financials dashboard carries the complete quarterly and annual income statement, balance sheet and cash-flow history, with derived figures flagged and every XBRL concept disclosed.
Open JNJ Financials →How JNJ trades — the working manual
Johnson & Johnson combines an innovative-medicine portfolio with a large medical-technology franchise. For the stock, durable prescription demand and procedure volumes must be weighed against patent cycles, pipeline outcomes and legal liabilities, while the two businesses carry different growth, margin and capital-allocation profiles.
What can move the tape
- 01Prescription volume, market share and new indications across the innovative-medicine portfolio.
- 02Procedure volumes, hospital capital budgets and product launches in medical technology.
- 03Clinical-trial results, regulatory approvals and the timing of pipeline commercialization.
- 04Operating cash flow, research investment and capital allocation across internal programs and acquisitions.
What can fool the read
- 01Patent expirations and biosimilar competition can change a major medicine's revenue quickly.
- 02Clinical, regulatory and product-quality events can alter expected cash flows abruptly.
- 03Product-liability litigation can create long-duration costs that do not follow operating trends.
- 04A diversified healthcare mix can conceal very different growth rates across medicines and devices.
No JNJ flags in the committed 2026-04-01–2026-08-21 archive. That means no session cleared this project's anomaly threshold; it does not mean trading volume was literally constant.
Not published yet. The local archive has 1 reported JNJ events—too few for a defensible gap-and-drift study. This missing block is an explicit indexing blocker.
Source map & freshness
| Block | What it uses | Vintage | Raw data |
|---|---|---|---|
| Identity | SEC issuer + primary security mapping | 2026-08-23 | JSON ↓ |
| Price & trend | Split-adjusted daily OHLCV + SPY comparison | 2026-08-21 | CSV ↓ |
| Options | End-of-day chain anomaly ranks | 2026-08-21 | Premium → |
| Ownership | Latest filings from 20 curated 13F managers | 2026-08-21 | Tool → |
| Financials | SEC EDGAR XBRL company facts | 2026-08-16 | JSON ↓ |
| Joined profile | The exact contract rendered by this page | 2026-08-23 | JSON ↓ |
JNJ stock questions
Is JNJ stock in an uptrend?+
JNJ is classified in the “established uptrend” regime as of 2026-08-21: the close is +6.0% from its 50-day average and +16.6% from its 200-day average. This describes the current tape. It is not a forecast.
What does unusual options activity in JNJ mean?+
Johnson & Johnson's OTM option chain produced an outlier relative to the scanner universe on at least one archived session. Call-side and put-side labels identify which book produced the signature; end-of-day chain data does not identify buyers, sellers, institutions or spread legs.
Are the JNJ 13F holdings current?+
No. 13F filings are delayed quarter-end snapshots and cover only the curated managers in this project. They are useful for documented ownership changes, not real-time positioning or complete institutional ownership.
Where are JNJ's income statement and cash flow?+
The dedicated JNJ Financials page contains the full quarterly and annual income statement, balance sheet and cash-flow history parsed from SEC EDGAR XBRL. This stock page carries only the latest filed snapshot.
Why is there no JNJ earnings-move base rate yet?+
The committed earnings archive does not yet contain enough reported events for a defensible company-level reaction study. The page leaves that block unpublished instead of presenting a tiny sample as a reliable base rate.